Current Neuropharmacology
Volume 17, 12 Issues, 2019
ISSN: 1875-6190 (Online)
ISSN: 1570-159X (Print)
This journal supports open access
ISSN: 1875-6190 (Online)
ISSN: 1570-159X (Print)
This journal supports open access
Ranking and Category
-
69th of 261 in
Neurosciences
-
40th of 261 in
Pharmacology & Pharmacy
Contents
Current Neuropharmacology, Volume 13 - Number 6
Editorial
The Role of Muscarinic Receptors in the Pathophysiology of Mood Disorders:A Potential Noveltreatment?
, 13(6): 739 - 749Won Je Jeon, Brian Dean, Elizabeth Scarr and Andrew Gibbons
DOI: 10.2174/1570159X13666150612230045
The Role of Muscarinic Receptors in the Pathophysiology of Mood Disorders:A Potential Noveltreatment?
Neural Basis of Anhedonia and Amotivation in Patients with Schizophrenia: The Role of Reward System
, 13(6): 750 - 759Jung Suk Lee, Suwon Jung, Il Ho Park and Jae-Jin Kim
DOI: 10.2174/1570159X13666150612230333
Neural Basis of Anhedonia and Amotivation in Patients with Schizophrenia: The Role of Reward System
Inhibitors of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase: New Targets for Future Antidepressants
, 13(6): 760 - 775Shintaro Ogawa and Hiroshi Kunugi
DOI: 10.2174/1570159X13666150612225212
Inhibitors of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase: New Targets for Future Antidepressants
Eicosanoids Derived From Arachidonic Acid and Their Family Prostaglandins and Cyclooxygenase in Psychiatric Disorders
, 13(6): 776 - 785Kunio Yui, George Imataka, Hiroyuki Nakamura, Naoki Ohara and Yukiko Naito
DOI: 10.2174/1570159X13666151102103305
Eicosanoids Derived From Arachidonic Acid and Their Family Prostaglandins and Cyclooxygenase in Psychiatric Disorders
Novel Therapeutic Approach for Autism Spectrum Disorder: Focus on SHANK3
, 13(6): 786 - 792Shigeo Uchino and Chikako Waga
DOI: 10.2174/1570159X13666151029105547
Novel Therapeutic Approach for Autism Spectrum Disorder: Focus on SHANK3
New Pharmacotherapy Targeting Cognitive Dysfunction of Schizophrenia via Modulation of GABA Neuronal Function
, 13(6): 793 - 801Takashi Uehara, Tomiki Sumiyoshi and Masayoshi Kurachi
DOI: 10.2174/1570159X13666151009120153
New Pharmacotherapy Targeting Cognitive Dysfunction of Schizophrenia via Modulation of GABA Neuronal Function
The Role of the Catechol-o-Methyltransferase (COMT) GeneVal158Met in Aggressive Behavior, a Review of Genetic Studies
, 13(6): 802 - 814Arqam Qayyum, Clement C. Zai, Yuko Hirata, Arun K. Tiwari, Sheraz Cheema, Behdin Nowrouzi, Joseph H. Beitchman and L. Kennedy
DOI: 10.2174/1570159X13666150612225836
The Role of the Catechol-o-Methyltransferase (COMT) GeneVal158Met in Aggressive Behavior, a Review of Genetic Studies
The Role of Topiramate in the Management of Cocaine Addiction: a Possible Therapeutic Option
, 13(6): 815 - 818Antonio Siniscalchi, Antonello Bonci, Nicola Biagio Mercuri, Domenico Pirritano, Aida Squillace, Giovambattista De Sarro and Luca Gallelli
DOI: 10.2174/1570159X13666150729222643
The Role of Topiramate in the Management of Cocaine Addiction: a Possible Therapeutic Option
Use of Push-Pull Superfusion Technique for Identifying Neurotransmitters Involved in Brain Functions: Achievements and Perspectives
, 13(6): 819 - 829Michaela M. Kraus and Athineos Philippu
DOI: 10.2174/1570159X13666150722233149
Use of Push-Pull Superfusion Technique for Identifying Neurotransmitters Involved in Brain Functions: Achievements and Perspectives
An Endogenous Tachykinergic NK2/NK3 Receptor Cascade System Controlling the Release of Serotonin from Colonic Mucosa
, 13(6): 830 - 835Shu-ichi Kojima, Atsushi Tohei, Masashi Ikeda and Naohiko Anzai
DOI: 10.2174/1570159X13666150825220524
An Endogenous Tachykinergic NK2/NK3 Receptor Cascade System Controlling the Release of Serotonin from Colonic Mucosa
Tyrosine Kinase Inhibitor as a new Therapy for Ischemic Stroke and other Neurologic Diseases: is there any Hope for a Better Outcome?
, 13(6): 836 - 844Iwona Gagalo, Izabela Rusiecka and Ivan Kocic
DOI: 10.2174/1570159X13666150518235504
Tyrosine Kinase Inhibitor as a new Therapy for Ischemic Stroke and other Neurologic Diseases: is there any Hope for a Better Outcome?
Erratum
  |
Editor-in-Chief
T.E. Salt
University College London
Institute of Ophthalmology
London EC1V9EL
UK
University College London
Institute of Ophthalmology
London EC1V9EL
UK
About the Journal
For Authors
For Librarians & Readers
Journal History
Current Neuropharmacology was introduced in 2003 with the assistance of Dr. T.E. Salt, who is the current acting Editor-in-Chief since 2003.
Scopus CiteScore Metrics: 4.28
New eBook
 |
Neurobiology of Mood DisordersYou can view the contents of this eBook [here] or purchase it [here]. |
Webmaster Contact: info@benthamscience.net